Pharmacokinetics of Nanomedicines
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Pharmacokinetics and Pharmacodynamics".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 1899
Special Issue Editor
Interests: biopharmacy; in vivo/in vitro models; cell culture; pharmacokinetics; PKPD; nanomedicine; cancer; oral delivery; lung delivery; brain delivery
Special Issue Information
Dear Colleagues,
As demonstrated by the recent progresses in vaccines and cancer therapy, nanomedicine could be viewed as a very promising strategy to significantly improve human health. The paradox is that the idea to use nanotechnology to enhance drug efficacy and tolerance was proposed more than 50 years ago; however, so few drug products have reached the market. One reason is that those drug delivery systems (DDS) are difficult to characterize and to produce at an industrial scale. One of the key features evaluated by drug agencies to approve new products is drug pharmacokinetics (i.e., absorption, distribution, metabolization and elimination of the drug from the body). Until very recently, the pharmacokinetics (PKs) of nanomedicines have been assessed using models initially designed for regular formulations. We now know that the fate of live organisms, of a nanoparticle encapsulating an active pharmaceutical ingredient (API), has to be studied with specific models since it is modified as soon as it comes into contact with living tissues or liquid. In order to help more DDS to reach the market and improve human health, the present Special Issue will gather the latest studies on this subject.
Prof. Dr. Frederic Lagarce
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanomedicines
- drug delivery systems
- pharmacokinetics
- PKPD
- in vivo/in vitro models
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
